Targeted Treatment Options for Patients With AML and FLT3 or IDH1/2 Mutations - a podcast by Clinical Care Options

In this podcast episode, Sarah M. Tinsley, PhD, APRN, AOCN, discusses targeted therapy with FLT3 and IDH1/2 inhibitors in AML, with a focus on the nursing perspective. Topics include:

• Approved and emerging treatment options for FLT3-mutated AML
• Management of adverse events associated with FLT3 inhibitors
• Therapies for IDH1- and IDH2-mutated AML
• Identifying and managing differentiation syndrome associated with IDH1/2 inhibitors

Presenters:

Sarah M. Tinsley, PhD, APRN, AOCN
Nurse Practitioner
Courtesy Assistant Professor
Department of Malignant Hematology
Moffitt Cancer Center
University of South Florida
Tampa, Florida

 

Further episodes of CCO Oncology Podcast

Further podcasts by Clinical Care Options

Website of Clinical Care Options